iBio (IBIO) Competitors $0.84 +0.02 (+2.92%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.83 -0.01 (-0.72%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IBIO vs. COEP, KALA, MNOV, GNTA, INMB, CUE, IMMX, SLGL, ALGS, and ALXOShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Coeptis Therapeutics (COEP), KALA BIO (KALA), MediciNova (MNOV), Genenta Science (GNTA), INmune Bio (INMB), Cue Biopharma (CUE), Immix Biopharma (IMMX), Sol-Gel Technologies (SLGL), Aligos Therapeutics (ALGS), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors Coeptis Therapeutics KALA BIO MediciNova Genenta Science INmune Bio Cue Biopharma Immix Biopharma Sol-Gel Technologies Aligos Therapeutics ALX Oncology Coeptis Therapeutics (NASDAQ:COEP) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings. Do insiders and institutionals hold more shares of COEP or IBIO? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer COEP or IBIO? iBio has a consensus target price of $5.00, suggesting a potential upside of 498.80%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, COEP or IBIO? Coeptis Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Does the media favor COEP or IBIO? In the previous week, iBio had 6 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 8 mentions for iBio and 2 mentions for Coeptis Therapeutics. iBio's average media sentiment score of 1.19 beat Coeptis Therapeutics' score of 0.84 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, COEP or IBIO? Coeptis Therapeutics has higher earnings, but lower revenue than iBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.12iBio$375K43.77-$24.91MN/AN/A Is COEP or IBIO more profitable? iBio's return on equity of -73.15% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -201.73% -108.46% iBio N/A -73.15%-45.51% SummaryiBio beats Coeptis Therapeutics on 9 of the 12 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$16.41M$863.38M$5.77B$21.40BDividend YieldN/A4.84%6.71%3.50%P/E RatioN/A1.0975.5429.64Price / Sales43.7726.53480.4249.00Price / CashN/A19.5636.9624.54Price / Book0.596.7211.444.55Net Income-$24.91M-$4.20M$3.28B$999.70M7 Day Performance2.12%0.53%0.96%0.57%1 Month Performance40.34%12.30%7.82%5.65%1 Year Performance-53.09%28.54%62.64%17.39% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio2.169 of 5 stars$0.84+2.9%$5.00+498.8%-54.6%$16.41M$375K0.00100News CoveragePositive NewsCOEPCoeptis Therapeutics1.3234 of 5 stars$13.65+1.4%N/A+231.6%$64.88MN/A-2.352Short Interest ↓Gap UpKALAKALA BIO2.8887 of 5 stars$8.78-4.7%$13.00+48.1%+148.7%$64.66M$3.89M-1.2930Trending NewsAnalyst UpgradeAnalyst RevisionGap DownMNOVMediciNova2.0262 of 5 stars$1.32+0.6%$7.00+430.3%-28.3%$64.37M$1M-5.2810Gap UpGNTAGenenta Science2.479 of 5 stars$3.50-0.4%$25.00+615.3%-23.4%$64.20MN/A0.007Gap DownHigh Trading VolumeINMBINmune Bio2.62 of 5 stars$2.24-7.1%$18.40+721.4%-67.5%$64.07M$10K-0.9010CUECue Biopharma1.2011 of 5 stars$0.82-0.9%N/A+23.8%$63.47M$9.29M-1.4660High Trading VolumeIMMXImmix Biopharma3.323 of 5 stars$2.10-4.1%$7.00+233.3%+2.4%$63.15MN/A-2.739Short Interest ↓SLGLSol-Gel Technologies1.3024 of 5 stars$21.00-7.4%N/A+311.1%$63.15M$11.54M-17.0750News CoverageShort Interest ↓Gap UpALGSAligos Therapeutics4.1251 of 5 stars$10.21+0.1%$50.00+389.7%-5.0%$62.74M$3.94M-0.5290High Trading VolumeALXOALX Oncology3.9728 of 5 stars$1.10-6.0%$3.30+200.0%-38.7%$62.65MN/A-0.5040News CoverageShort Interest ↓Gap Down Related Companies and Tools Related Companies COEP Alternatives KALA Alternatives MNOV Alternatives GNTA Alternatives INMB Alternatives CUE Alternatives IMMX Alternatives SLGL Alternatives ALGS Alternatives ALXO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
